| Previous Close | 2.95 |
| Open | 2.95 |
| Day High | 3.09 |
| Day Low | 2.91 |
| 52-Week High | 7.33 |
| 52-Week Low | 2.05 |
| Volume | 203,178 |
| Average Volume | 1.87M |
| Market Cap | 47.67M |
| PE | -3.71 |
| EPS | -0.8 |
| Moving Average 50 Days | 2.5 |
| Moving Average 200 Days | 2.73 |
| Change | 0.02 |
Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
GlobeNewswire Inc.
Mar 09, 2026 12:30 PM GMT
-- The Phase 2b study to assess enobosarm’s ability to preserve lean mass, physical function, and bone as well as burn more fat to produce greater quality and quantity of weight loss in older patients with obesity receiving semaglutide -- -- Interim
Veru to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
GlobeNewswire Inc.
Feb 19, 2026 1:30 PM GMT
MIAMI, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced that Mitch
Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th
GlobeNewswire Inc.
Feb 04, 2026 1:30 PM GMT
MIAMI, FL, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced it wil